JAK2 and acute lymphoblastic leukemia: DS-ALL is distinguished by the similarly high presence of both CRLF2-rearrangements (60%) (with JAK2 mutations at 32%), with a higher proportion of RAS-MAPK pathway mutations (36%) [20, 21].